Navigation Links
Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device
Date:5/12/2008

ate the pivotal trial may enable us to raise the capital needed to implement our clinical and regulatory plans for SEPET."

About Arbios' SEPET(TM) Liver Assist Device

The SEPET(TM) Liver Assist Device is a sterile, disposable cartridge containing microporous hollow fibers with proprietary permeability characteristics. When a patient's blood is passed through these fibers, blood plasma components of specific molecular weights are expressed through the micropores, thereby cleansing the blood of harmful impurities (e.g., hepatic failure toxins as well as various mediators of inflammation and inhibitors of liver regeneration). These substances would otherwise progressively accumulate in the patient's bloodstream during liver failure, causing hypotension, increasing risk of sepsis development and accelerating damage to the liver, lungs and other organs, including the brain and kidneys, and suppressing the function and regeneration of the liver. SEPET(TM) is designed for use with standard blood dialysis systems available in hospital intensive care units.

According to the American Liver Foundation, liver disease is among the top seven causes of death in adults in the United States between the ages of 25 - 64. In fact, one out of every 10 Americans has some form of liver disease. There is currently no satisfactory therapy available to treat patients in liver failure, other than maintenance and monitoring of vital functions and keeping patients stable through provision of intravenous fluids and blood products, administration of antibiotics and support of vital functions, such as respiration.

About Arbios Systems

Arbios Systems, Inc. is developing proprietary medical devices and cell-based therapies to enhance the survival of millions of patients each year who experience, or are at risk for, life-threatening episodes of liver failure. The Arbios product candidate portfolio includes the SEPET(TM) Liver Assist Device, a novel blood purificatio
'/>"/>

SOURCE Arbios Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
2. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
3. Strykers Biotech Division Receives FDA Warning Letter
4. Repligen Receives FDA Fast Track Designation for RG1068 for Pancreatic Imaging
5. Iomai Receives HHS Approval to Begin Phase 2 Trial of H5N1 Influenza Adjuvant Patch
6. Genta Receives Key Patent Related to Oral Gallium Compound G4544
7. QMed, Inc. Receives 2-Year Extension of Medicare Coordinated Care Demonstration Project by CMS
8. Thermo Fisher Scientific Receives FDA Clearance for MRSA Test Medium
9. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
10. DermaGen AB Receives Over 1 Million Euros From a New Share Issue
11. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... VIEW, Calif. , July 24, 2014  IRIDEX ... it will release its second quarter 2014 financial results ... 2014. In conjunction with the release, the Company ... at 5:00 p.m. Eastern Time on ... of the quarter and other business developments. ...
(Date:7/24/2014)... 2014 Omnicell, Inc. (NASDAQ: ... supply management solutions and analytics software for healthcare ... to discuss the Company,s Second Quarter 2014 financial ... earnings conference call and webcastWhen: , July ... chairman, president and chief executive officer ...
(Date:7/24/2014)... N.J., July 24, 2014  IGI Laboratories, Inc. (NYSE MKT: ... manufacturing company, announced its financial results for the second quarter ... , Total revenues of $6.5 million in the ... same quarter in 2013 , Total revenues of $13.3 ... increase of 78% over the same period in 2013 ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... New results from the largest multicenter clinical trial for ... the International Society for Heart & Lung Transplantation (ISHLT) ...  Results show clinical benefit for the use of Everolimus ... 721 randomized patients at 67 medical centers spanning 5 ...
... April 14, 2011 Oxford Finance Corporation (Oxford), a ... a $2 million equipment loan with Synta Pharmaceuticals Corp. ... compounds for use in Synta,s ongoing clinical trials in ... "Synta Pharmaceuticals has a diverse drug pipeline, including ...
Cached Medicine Technology:Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 2Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 3Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 4Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp. 2
(Date:7/25/2014)... when genes are switched on or off plays a ... regulate metabolism, UT Southwestern Medical Center researchers have found., ... treat obesity and diabetes, since the transcription factor involved ... to influence the body,s sensitivity to insulin and leptin ... body,s regulation of food intake and sugar disposal, and ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Innerspire, LLC ... joined the company as a Creative Enrollment Specialist. In ... relationship building skills as well as his accomplished design ... small business clients, and to service the creative ... Additionally, Greg will work with small business owners and ...
(Date:7/25/2014)... The American Brain Tumor Association (ABTA) ... CommYOUnity™” during its annual patient and family conference in ... brain tumor community as we – the first and ... services and funding brain tumor research – extend our ... tumor awareness and getting our materials and services into ...
(Date:7/25/2014)... July 25, 2014 There are 700,000 people ... diagnosed each day. Though when someone hears the words, “you ... are unsure of the next step and where to turn. ... figure out that next step by providing and pursuing the ... than Brian Olson, member of the ABTA’s Board of Directors ...
(Date:7/25/2014)... Progress in understanding the molecular genetics of brain ... brain tumor treatments, according to Patrick Wen, MD, professor ... for Neuro-Oncology, Dana-Farber Cancer Institute. , At the American ... in Chicago, July 25-26, Dr. Wen will moderate a ... the development of new treatments and advancing strategies to ...
Breaking Medicine News(10 mins):Health News:Manipulating key protein in the brain holds potential against obesity and diabetes 2Health News:Innerspire, LLC Continues National Expansion 2Health News:Innerspire, LLC Continues National Expansion 3Health News:Innerspire, LLC Continues National Expansion 4Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 3Health News:American Brain Tumor Association Board of Directors Member Shares Story of Brain Tumor Survivorship 2Health News:American Brain Tumor Association Board of Directors Member Shares Story of Brain Tumor Survivorship 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 2Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 3Health News:Immunotherapy, Targeted Molecular Therapies Among Promising New Treatments for Brain Tumors 4
... its truth when then Researchers of Arizona University did a ... D.Martinez and collegues , girls who become overweight or obese ... have a sevenfold increased risk of developing asthma .The boys ... if they are obese , the researchers say. , The ...
... research that suggests high doses of vitamin E may ... prevalent diseases in the world with many ravaging complications, ... heart disease, eye damage, kidney failure, non healing ulcers ... of the nervous system. ,Diabetes is caused by ...
... of Pfizer. The pharmaceutical giant has announced that it ... by the AIDS virus. The decision by the Pfizer comes ... a landmark case against pharmaceutical companies. In an announcement ... be given free of cost to battle HIV through a ...
... Azad Medical College, New Delhi has created history of ... from the American patent office for his technique in ... ,A few weeks ago the American patent office granted ... was able to regenerate organs like the uterus, urethra ...
... West is now sitting up and taking in the aroma ... spices are now the subjects of research by scientists at ... C. Fung and colleagues who conducted the study opine that ... can also double up as an anti bacterial agent. ...
... a little quality time with one's spouse and other partners ... pressure. In a study that used portable monitors to ... pressure was lowest when they were with their partners, regardless ... of the State University of New York, the lead study ...
Cached Medicine News: